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Leukocyte adhesion to the vascular endothelium con-
tributes to many immunological and inflammatory dis-
orders. These processes have been shown to be medi-
ated by bradykinin receptor type 2 (B2R) and dopamine 
receptor type 2 (D2R). In a previous study, we reported 
the formation of a B2R-D2R heterodimer, possibly alter-
ing cellular functions. Hence, in the present study, we 
examined the effect of co-activation of endothelial cells 
with B2R and D2R agonists on the interaction of these 
cells with neutrophils. Bradykinin, the main B2R agonist, 
significantly increased cell adhesion, and this effect was 
reversed when the endothelial cells were additionally co-
treated with a selective D2R agonist, sumanirole. These 
results were dependent on the incubation time, showing 
an opposite tendency after prolonged stimulation. Sig-
nificant changes in the expression of adhesion proteins, 
such as E-selectin and intercellular adhesion molecule 
1 in endothelial cells were observed. Additionally, the 
cells preincubated with tumor necrosis factor-α showed 
decreased cell adhesion and IL-8 release after long in-
cubation with both agonists. The modulation of cell ad-
hesion by D2R and B2R seem to be mediated via STAT3 
phosphorylation. In summary, this study demonstrated 
a protective role of D2R in neutrophil-endothelial cell 
adhesion induced by bradykinin, especially in cytokine-
stimulated endothelial cells.
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INTRODUCTION
Initial stages of the inflammatory response of a vascu-
larized tissue to various cellular lesions involve leukocyte 
recruitment, adhesion to the endothelium, and migration 
to the affected region. During these events, numerous 
molecular interactions occur between specific proteins 
that are present in the membranes of both endothelial 
cells and leukocytes (Langer & Chavakis, 2009). Leuko-
cyte recruitment is initiated by several chemokines, espe-
cially interleukin-8 (IL-8), and is followed by leukocyte 
rolling along the vascular surface, which engages a group 
of adhesion proteins called selectins. In turn, firm adhe-
sion and sticking of leukocytes to the endothelium takes 
place via an interaction between leukocyte integrins and 
proteins of the endothelial cell surface, such as the inter-
cellular and vascular cell adhesion molecules 1 (ICAM-1 
and VCAM-1, respectively). Next, adherent leukocytes 
start migration from the vascular wall into the interstitial 
space, where they release proteolytic enzymes, oxygen 
free radicals, and other factors to destroy the inducers 
of the inflammatory response. All these processes are 
strictly regulated by proinflammatory cytokines produced 
by both leukocytes and endothelial cells, including tu-
mor necrosis factor α (TNF-α) and interleukin-1, which 
up-regulate the expression of different adhesion mole-
cules in cells (Langer & Chavakis, 2009).
Additional substances that accumulate at the inju-
ry site during inflammation, such as kinin peptides play 
an important role in leukocyte adhesion (Guevara-Lo-
ra et al., 2011; Figueroa et al., 2015). Kinins, including 
bradykinin (BK), kallidin, and their metabolites without 
arginine at the C-end, are well known pro-inflammato-
ry peptides, and are recognized by specific receptors – 
bradykinin receptor type 1 and type 2 (B1R and B2R, 
respectively). These receptors belong to a large super-
family of G protein-coupled receptors (GPCRs). Des-
Arg metabolites activate mainly B1R, while BK and kalli-
din exert their biological effects via B2R (Bhoola et al., 
1992; Leeb-Lundberg et al., 2005). Activation of B2R is 
particularly essential for the regulation of vascular tone 
and permeability, which control arterial pressure and 
cell migration through microvessel walls (Ishihara et al., 
2002; Su, 2015). BK has been shown to increase mono-
cyte adhesion to endothelial cells by enhancement of the 
expression of adhesion proteins, ICAM-1 and macro-
phage-1 antigen (Mac-1, CD11b/CD18) respectively, in 
human endothelial cells and monocytes (Guevara-Lora et 
al., 2014). In contrast, a reduced amount of rolling and 
adherent leukocytes was observed in mice with induced 
global cerebral ischemia treated with a B2R antagonist 
(Lehmberg et al., 2003). Moreover, the participation of 
BK in induction of IL-8 production by lung fibroblasts 
and human airway smooth muscle cells has also been 
documented (Koyama et al., 2000; Roscioni et al., 2009).
Other receptors belonging to the GPCR family as well 
as the dopamine receptors are abundantly expressed in 
the cardiovascular system, where they regulate vasodila-
Vol. 65, No 3/2018
367–375
https://doi.org/10.18388/abp.2018_2641
368           2018A. Niewiarowska-Sendo and others
tation (Missale et al., 1998). These receptors are classified 
into two major groups: the D1 and D2 classes. The for-
mer group includes subtypes D1 and D5 while the latter 
one comprises subtypes D2, D3, and D4. They differ in 
their ability to modulate the production of cAMP. D1-
class receptors stimulate the production of cAMP, while 
receptors from the D2 class negatively regulate cAMP 
production. The dopamine receptor type 2 (D2R) has 
been demonstrated to be broadly involved in the regula-
tion of anti-inflammatory responses. D2R agonists have 
been reported to enhance the production of interleukin 
10, i.e. an anti-inflammatory cytokine, in human T-lym-
phocytes (Besser et al., 2005). By contrast, D2R silencing 
in mouse renal proximal tubule cells increased the ex-
pression of TNF-α and monocyte chemoattractant pro-
tein-1 levels, while the treatment with the D2R agonist 
abolished an angiotensin II-induced effect on the release 
of these proinflammatory factors (Zhang et al., 2012). 
Moreover, D2R stimulation increased the expression of 
endogenous antioxidants, which prevent endothelial cell 
apoptosis (Horke et al., 2007). The importance of this 
receptor in the down-regulation of von Willebrand fac-
tor secretion, resulting in reduced endothelial activation 
during inflammation, has been reported as well (Zarei et 
al., 2006).
Recently, numerous studies have been focused on co-
operation between GPCRs, which may result in changes 
in ligand affinities and cell signaling pathways of each 
receptor, causing significant modifications of cellular 
processes (Ferre et al., 2014). A considerable number of 
interactions of B2R and D2R with other GPCRs, result-
ing in oligomeric complexes, has been recently reported 
(Guevara-Lora et al., 2016). Moreover, our group demon-
strated for the first time the formation of a functional 
heterodimer between B2R and D2R, capable of modu-
lating cell responses, such as the intracellular Ca2+ and 
cAMP concentration (Niewiarowska-Sendo et al., 2017). 
All these facts suggest that the interaction between B2R 
and D2R can have a consequence in the regulation of 
neutrophil adhesion to endothelial cells. To support of 
this hypothesis, in the present study, we investigated the 
effects of co-treatment with BK and sumanirole (SUM), 
specific agonists for B2R and D2R, respectively, on pro-
cesses involved in neutrophil-endothelial cell adhesion.
MATERIALS AND METHODS
Chemicals. BK was supplied by Bachem (Bubendorf, 
Switzerland). Antibiotics, antimycotics, cell culture medi-
um, and fetal bovine serum (FBS) were purchased from 
Corning (Corning, NY). Cell Tracker Red CMTPX was 
supplied by Molecular Probes (Eugene, OR). Bacitracin, 
captopril, endothelial cell growth supplement, heparin, 
icatibant (HOE 140), 2-mercaptomethyl-3-guanidinoeth-
ylthiopropanoic acid, protease inhibitors, SUM maleate, 
S-(−)-eticlopride hydrochloride (eticlopride), and other 
standard chemicals were obtained from Sigma-Aldrich 
(St Louis, MO). Human TNF-α was purchased from 
Thermo Fisher Scientific (Waltham, MA).
Antibodies. Rabbit polyclonal antibody against E-
selectin (ab185698) was purchased from Abcam (Cam-
bridge, England). Human antibodies against ICAM-1, 
VCAM-1, and E-selectin conjugated with phycoerythrin 
(322708, 305806, and 322606, respectively) were sup-
plied by Biolegend (San Diego, CA). Rabbit monoclonal 
antibodies against ICAM-1, signal transducer and acti-
vator of transcription 3 (STAT3), and phospho-STAT3 
(#4915, #4904, and #9145, respectively) were obtained 
from Cell Signaling Technology (Danvers, MA). Mouse 
monoclonal antibody against β-actin (MAB8929) and 
goat polyclonal antibody against mouse or rabbit IgG 
conjugated with horseradish peroxidase (HAF007 and 
HAF008, respectively) were purchased from R&D Sys-
tems (Minneapolis, MN).
Cell culture. The human endothelial cell line (HUV-
EC-C; ATCC® CRL-1730TM) purchased from ATCC 
(Manassas, VA) was cultured in F-12K medium (Kaighn’s 
Modification of Ham’s F-12 Medium) supplemented 
with 10% FBS, 1 U/ml penicillin, 1 µg/ml streptomy-
cin, 2.5 µg/ml amphotericin B, 50 µg/ml endothelial cell 
growth supplement, and 100 µg/ml heparin at 37°C in a 
humidified atmosphere containing of 5% CO2. Twenty-
four hours before the experiments, cells were starved 
of the growth factors and the cells were stimulated in 
F-12K medium suplemented with 1% FBS and kininase 
inhibitors (10 µM 2-mercaptomethyl-3-guanidinoethylthi-
opropanoic acid, 20 µM captopril, and 500 µM bacitra-
cin).
Neutrophil adhesion to endothelial cells. Human 
polymorphonuclear cells (PMN) were isolated as de-
scribed previously (Zawrotniak et al., 2017) from freshly 
EDTA-treated whole-blood samples obtained from the 
Regional Blood Donation Center (Krakow, Poland), 
which complies with the requisite of confidentiality as-
surance for human participants. Isolated PMN were 
suspended in RPMI-1640 medium and loaded with Cell 
Tracker Red CMTPX in RPMI for 30 min at 37°C, fol-
lowing the manufacturer’s instructions, and then placed 
on a monolayer of endothelial cells stimulated as de-
scribed below. Detailed description of the cell adhesion 
analysis was provided elsewhere (Guevara-Lora et al., 
2011).
Confluent endothelial cells seeded in a 96-well micro-
plate were pretreated or not pretreated with 10 ng/ml 
TNF-α for 24 hours and subsequently stimulated with 
100 nM BK, 100 nM SUM or both agonists for 6, 12, 
and 24 hours. Because cellular adhesion is a dynamic 
process depending on many factors, e.g. the presence 
of chemoattractants, in this study, we decided to evalu-
ate the adhesion of PMN to endothelial cells at different 
intervals of the incubation time (Mestas & Ley, 2008). 
Some samples were additionally preincubated for 30 
minutes with B2R or D2R antagonists (10 µM HOE 140 
or 10 µM eticlopride, respectively) before cell stimulation 
with agonists.
Flow cytometry analysis. Confluent endothelial cells 
were stimulated with 100 nM BK, 100 nM SUM, or 
both agonists for 6 hours, i.e. an optimal time for re-
location of adhesion molecules to the cell membrane 
(Scholz et al., 1996). After the incubation, the cells were 
washed, detached, and incubated for 30 min at 4°C with 
phycoerythrin-conjugated antibodies at dilutions: 1:125 
for ICAM-1 and 1:150 for VCAM-1 and E-selectin. Af-
ter washing and resuspension, the mean fluorescence of 
the labeled cells was analyzed in a flow cytometer (Bec-
ton Dickinson, Franklin Lakes, NJ). Nonspecific fluores-
cence was determined using an isotype-matched human 
IgG (409301, Biolegend).
Protein analysis by Western blotting. Conflu-
ent endothelial cells were treated with 100 nM BK, 
100 nM SUM, or both agonists for 6 and 24 hours to 
determine ICAM-1 and E-selectin or for 15 minutes to 
measure STAT3 and STAT3 phosphorylated at Tyr-705 
(pSTAT3) in the medium supplemented with kininase in-
hibitors. Thereafter, cell lysates were prepared with Lae-
mmli lysis buffer (0.125 M Tris-HCl, 20% glycerol, 4% 
sodium dodecyl sulfate (SDS), 400 mM dithiothreitol, 
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0.004% bromophenol blue, pH 6.8) supplemented with 
5 mM sodium fluoride and 1 mM sodium orthovana-
date. Equal volumes of each sample were subjected to 
SDS-PAGE (polyacrylamide gel electrophoresis) in 12% 
gel. Resolved proteins were transferred to polyvinylidene 
difluoride membranes (Sigma-Aldrich) in Tris/glycine 
buffer (25 mM Tris, 192 mM glycine, 20% methanol, 
pH 8.3) for 1 hour. After overnight blocking with 5% 
non-fat milk, the membrane was incubated for 24 hours 
at 4°C with primary antibodies at dilutions of 1:100 for 
anti-E-selectin, 1:500 for anti-ICAM-1, 1:1000 for anti-
pSTAT3 and anti-STAT3, and 1:2000 for anti-β-actin. 
Next, after extensive washing, the membrane was in-
cubated with the respective secondary antibody conju-
gated with horseradish peroxidase at a 1:1000 dilution. 
After one-hour incubation and extensive washing, enzy-
matic reaction was performed with Immobilon Western 
Chemiluminescent HRP Substrate (Sigma-Aldrich) in ac-
cordance with the manufacturer’s instructions. β-Actin 
was analyzed as a housekeeping protein in every blot as 
a normalization control.
Determination of interleukin-8 concentration by 
ELISA. Confluent endothelial cells were pretreated or 
not with 10 ng/ml TNF-α for 24 hours and subsequently 
stimulated for 6 hours with 100 nM BK, 100 nM SUM, 
or both agonists. Some samples were additionally prein-
cubated with 10 µM HOE 140 or 10 µM eticlopride for 
30 minutes prior to the induction with receptor agonists. 
The interleukin-8 concentration in the medium was de-
termined using a specific ELISA kit (BD Biosciences) 
according to the manufacturer’s instructions and normal-
ized to the amount of sample protein detected with the 
Lowry method. Absorbance was measured with a Pow-
erWave X-Select microplate reader (BioTek Instruments, 
Winooski, VT) at 450 nm.
Statistical analysis. Statistical analysis was performed 
with the R environment (R Core Team, 2016). Repre-
sentative data from at least three experiments were ex-
pressed as mean values ± S.D. Student’s t-test was used 
for statistical comparisons of mean values, and data were 
considered significant at p<0.01 or p<0.05, depending on 
the analyzed samples.
RESULTS
Co-treatment of endothelial cells with B2R and D2R 
agonists alters neutrophil adhesion
The fact that kinin peptides induce leukocyte adhesion 
to endothelial cells is well known (Guevara-Lora et al., 
2011; Guevara-Lora et al., 2014; Figueroa et al., 2015). 
In order to investigate the effect of D2R activation on 
BK-induced adhesion, endothelial cells were stimulated 
with 100 nM BK and 100 nM SUM and co-stimulated 
with both agonists at the same concentration at differ-
ent incubation time: 6, 12, and 24 hours. The choice of 
the agonist concentration was supported by information 
from earlier reports, in which 100 nM BK was consid-
ered to represent a pathological level (Blais et al., 2000) 
and 100 nM SUM, one of the most selective D2R ago-
nists, was close to a EC50 range in which this substance 
exhibited efficient binding to D2 receptors on cell mem-
branes (McCall et al., 2005). In addition, during optimiza-
tion studies, different concentrations of agonists (1 nM 
and 100 nM) did not cause substantial differences in the 
interaction between PMN and endothelial cells (see sup-
plementary results – Fig. S1 at www.actabp.pl). Specific 
inhibitors were used to avoid bradykinin degradation by 
kininases. The results of the adhesion assay are presented 
as the mean percentage of PMN adhesion to endothelial 
cells in relation to the untreated cells, which is assumed 
as 100% (Fig. 1A). A significant increase in the adhe-
sion yield was observed after 6 hours of endothelial cell 
treatment with BK, compared to the untreated cells (by 
40%). On the contrary, simultaneous stimulation with 
both agonists led to total abolition of the BK-induced 
effect, and even a significant decrease in adhesion was 
observed (by 27%, compared to the untreated cells). The 
prolonged stimulation of the cells with BK maintained 
the high level of PMN adhesion (an increase by 26% 
and 13%, after 12 hours and 24 hours, respectively). In 
the case of cells co-stimulated with BK and SUM for the 
longer periods (12 and 24 hours), PMN adhesion was 
significant increased (by 44% and 50%, compared to the 
untreated cells for 12-h and 24-h incubation, respective-
ly). The SUM-treated cells showed no changes regardless 
of the incubation time.
Figure 1. Neutrophil adhesion to endothelial cells treated with 
B2R and D2R agonists.
Labeled PMN were placed on confluent endothelial cells stimulat-
ed with 100 nM BK, 100 nM SUM, or both agonists simultaneously 
for 6, 12, and 24 hours (A). Some samples were additionally pre-
incubated with 10 μM HOE 140 or 10 μM eticlopride 30 minutes 
before receptor activation with the agonists (B, C). The bars rep-
resent the mean percentage of PMN adhesion to endothelial cells 
in relation to: (A) untreated cells, (B) BK-treated cells at the corre-
sponding time, and (C) BK+SUM-treated cells at the corresponding 
time, assumed to have values equal to 100%. In each case, at least 
three experiments were performed in triplicates. *p<0.05 between 
the indicated samples.
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A preincubation of endothelial cells with respective 
B2R and D2R antagonists, i.e. HOE 140 and eticlopride, 
confirmed a possible mediation of these receptors in the 
observed effects. For clearer presentation of the induced 
effects, the results from these experiments were pre-
sented as the average percentage of PMN adhesion to 
endothelial cells in comparison to different control sam-
ples: cells treated with BK at different lengths of incuba-
tion (Fig. 1B) and cells treated with BK+SUM, also at 
different incubation periods (Fig. 1C), were assigned with 
a value of 100%. The treatment of the HOE 140-prein-
cubated cells with BK resulted in a significant reduction 
of cell adhesion by 24% and 20% after 6 and 12 hours, 
respectively, compared to the corresponding control 
sample without the antagonist treatment. After 24 hours 
of incubation with BK, the pretreatment with the B2R 
antagonist did not change the effect induced by BK 
(Fig. 1B). In turn, the cell pretreatment with eticlopride 
did not significantly change the BK action (Fig. 1B). 
The most interesting observations are related to the re-
sults of the cells stimulated with BK+SUM after the pre-
treatment with the antagonists (Fig. 1C). In this case, the 
B2R antagonist was able to invert the effect achieved by 
the cells after 6-h incubation with BK+SUM, showing 
that PMN adhered to HOE 140-preincubated endothe-
lial cells more strongly (by 20%) compared to cells stim-
ulated with BK+SUM but without the antagonist pre-
treatment. After the longer incubation with the agonists, 
the pretreatment with HOE 140 caused only a slight re-
duction of neutrophil-endothelial adhesion (by 11% and 
14% for 12-h and 24-h incubation, respectively). The 
D2R antagonist caused similar effects. Short stimula-
tion of the eticlopride-pretreated cells with both agonists 
(6 hours) enhanced PMN adhesion (by 55%); in turn, a 
significant decrease in this level (by 18%) was achieved 
upon the longer stimulation with BK+SUM (24 hours). 
The use of antagonists did not cause any changes in the 
cells stimulated only with SUM (data not shown). There-
fore, simultaneous activation of D2R and B2R may re-
sult in reduction of BK-induced adhesion of leukocytes 
to endothelial cells. Nevertheless, this effect is dependent 
on the time of stimulation with agonists, showing that 
longer stimulation can invert the observed adhesion in-
hibition.
B2R and D2R agonists modify neutrophil adhesion to 
cytokine-pretreated endothelial cells
The adhesion of leukocytes to the endothelium is 
strictly associated with the action of inflammatory cy-
tokines, including TNF-α. Since BK is a pro-inflammato-
ry factor that can induce cytokine release in cells, in this 
study, we investigated how the effect induced by BK 
and SUM in “resting” cells can be disturbed when the 
cells were previously treated with TNF-a. We observed 
significant changes in the PMN adhesion to TNF-α-
preincubated endothelial cells after the treatment with 
the B2R and D2R agonists (Fig. 2). The results were 
presented as the change in cell adhesion after stimulation 
with the agonists in comparison to the values achieved 
in the non-stimulated cell at the corresponding incuba-
tion time. Cell adhesion was significantly enhanced when 
the endothelial cells were treated with BK, and this ef-
fect was dependent on the incubation time (by 15%, 
16%, and 68% for 6, 12 and 24 hours, respectively). 
In turn, in contrast to the adhesion observed in the cy-
tokine non-pretreated cell, SUM caused a slight but sig-
nificant inhibition of neutrophil adhesion to endothelial 
cells. This effect was also dependent on the incubation 
time, showing the highest inhibition after 24 hours (by 
8%, 9%, and 22% for 6, 12, and 24 hours, respectively). 
The most unexpected results were obtained after incuba-
tion of the cells with BK+SUM. In these samples, the 
BK-induced effect on PMN adhesion was completely 
abolished, achieving even an inhibition of 16% below 
Figure 2. Neutrophil adhesion to TNF-α-treated endothelial cells 
after stimulation with B2R and D2R agonists. 
Confluent cells were pretreated with 10 ng/ml TNF-α for 24 hours. 
After stimulation with 100 nM BK, 100 nM SUM, or both agonists 
simultaneously for 6, 12, and 24 hours, the cells were incubated 
with PMN labeled with fluorescence dye. The bars represent the 
mean values ± S.D. calculated as the percentage of PMN adhesion 
to endothelial cells in relation to TNF-a-stimulated cells, but not 
treated with the agonists, assumed to be 100%. At least three ex-
periments in duplicate were performed. *p<0.05 between the indi-
cated samples.
Figure 3. Adhesion proteins in endothelial cell membrane after 
stimulation with B2R and D2R agonists. 
After 6-h stimulation with 100 nM BK, 100 nM SUM, or both ago-
nists simultaneously, confluent cells were analyzed by flow cytome-
try. Labeled antibodies to E-selectin (A), ICAM-1 (B), and VCAM-1 (C) 
were used. The values show the average percentage of changes in 
the mean fluorescence intensity (MFI) in comparison to the value 
obtained for the untreated cells, assumed to be 100%. *p<0.05 
versus untreated cells, #p<0.05 versus BK-treated cells.
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the value of untreated cells after 24 hours of incuba-
tion. Hence, this study clearly demonstrated a different 
response of activated endothelial cells when they are si-
multaneously incubated with selective agonists to B2R 
and D2R.
Effect of BK and SUM on the expression of adhesion 
proteins in endothelial cells
The adhesion of neutrophils to the endothelium implies 
rearrangement of various adhesion molecules in both neu-
trophils and endothelial cells. Here, we studied the effect 
of BK and SUM on the extracellular and total expression 
of the most important adhesion proteins in endothelial 
cells, i.e., E-selectin, ICAM-1, and VCAM-1. The flow 
cytometry studies allowed determining the presence of 
these proteins at the cell membrane (Fig. 3), whereas 
the total protein production was monitored with West-
ern blotting (Fig. 4). The results from flow cytometry 
showed increased expression of E-selectin (Fig. 3A) and 
ICAM-1 (Fig. 3B) after 6h stimulation with BK, by 27% 
and 17%, respectively, while no significant differences 
were noticed in VCAM-1 protein expression (Fig. 3C). 
In turn, the co-treatment with BK and SUM significantly 
inhibited the expression of E-selectin and ICAM-1 (by 
15% and 25%, respectively), but VCAM-1 expression 
did not change. On the other hand, the cell stimulation 
with SUM did not influence the expression of adhesion 
molecules in endothelial cells.
Since significant differences in PMN-endothelial cell 
adhesion were observed after 24-h incubation with BK 
and SUM, we evaluated the total production of E-selec-
tin and ICAM-1 by endothelial cells induced with these 
two substances for different incubation periods. From 
Western blotting images two bands near 67 and 89 kDa 
were detected, corresponding to E-selectin and ICAM-1 
(Fig. 4A). These results indicated a significant time-de-
pendent modification of the expression of these proteins 
in endothelial cells. The densitometric analysis of these 
bands was performed to calculate the protein content, 
which was normalized to the amount of β-actin protein. 
The resulted values were compared to those obtained 
for the untreated cells, which was assumed to be 1. The 
expression of E-selectin (Fig. 4B) as well as ICAM-1 
(Fig. 4C) significantly increased after 6h incubation with 
BK. The values obtained for these samples were 1.37 
and 1.25, respectively. Similarly, cells incubated with 
SUM exhibited higher amounts of both proteins, com-
pared to the untreated cells, reaching a relative E-selectin 
and ICAM-1 expression level of 1.52 and 1.32, respec-
tively. In the case of cells stimulated with BK+SUM si-
multaneously, the results for both proteins were strongly 
enhanced compared to the values observed after the 
treatment of endothelial cells with BK or SUM alone. In 
these samples, the calculated values were 1.97 and 1.79, 
respectively, for E-selectin and ICAM-1. The longer 
stimulation with the agonists caused slight changes in 
the ICAM-1 expression only (1.31, 1.24, and 1.22 for 
the BK-, SUM-, and BK+SUM-treated cells, respective-
ly). However, no significant differences were observed 
in the expression of E-selectin after the 24-h treatment 
with the agonists. Therefore, BK and SUM induced a 
quick production of adhesion molecules in the endothe-
lial cells, which was significantly enhanced when the cells 
were simultaneously stimulated with both agonists. These 
effects were attenuated after longer stimulation.
Effect of B2R and D2R agonists on interleukin-8 
production by endothelial cells
Interleukin-8, i.e. a chemotactic factor released from 
endothelial cells, attracts neutrophils during inflamma-
tory processes. Hence, in this study, we also examined 
the role of BK and SUM in the regulation of IL-8 pro-
duction by endothelial cells. Indeed, cells that were not 
pretreated with TNF-α did not show any significant 
changes in IL-8 production after the receptor agonist 
treatment (data not shown). However, in the TNF-α-
stimulated cells, bradykinin caused increased IL-8 release, 
compared with the untreated cells (by 35%), whilst re-
duced cytokine production was observed (by 33%) in the 
SUM-treated cells (Fig. 5A). In turn, the cell stimulation 
with BK and SUM simultaneously led to total abolition 
of the BK- and SUM-induced effects, exhibiting values 
similar to those obtained for the untreated cells. To con-
firm the mediation of B2R and D2R in cytokine release, 
Figure 4. Effect of B2R and D2R agonists on the expression of E-selectin and ICAM-1 in endothelial cells. 
Confluent cells were treated with 100 nM BK, 100 nM SUM, or both agonists simultaneously for 6 or 24 hours. The level of adhesion 
protein expression was evaluated by Western blotting (A) and the bands obtained for E-selectin (B) and ICAM-1 (C) were analyzed by 
densitometry. The figures represent mean values ± S.D. from two experiments, compared to the value obtained for the untreated cells 
assumed to be 1 (dashed line). *p<0.01 versus cells treated with BK, #p<0.01 versus cells treated with SUM.
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some experiments were also performed in cells pretreat-
ed with specific antagonists. HOE 140 inverted the BK-
induced production of IL-8, but had no significant effect 
on the SUM- and BK+SUM-stimulated cells (Fig. 5B). 
In turn, eticlopride effectively inhibited the effect caused 
by BK+SUM-stimulation of cells, exhibiting a significant 
increase in IL-8 production (by 32%, compared to the 
value obtained in cells treated only with eticlopride). No 
significant changes were observed in the BK- or SUM-
stimulated cells after the preincubation with the D2R 
antagonist (Fig. 5C). It should also be noted that the an-
tagonists did not exert any important influence on the 
cytokine release by the endothelial cells. The IL-8 con-
centration in the untreated cells, regardless of antagonist 
preincubation, was comparable, reaching a mean value of 
14 142 pg/mg of protein.
Co-treatment of endothelial cells with B2R and D2R 
agonists influences STAT3 phosporylation
STAT3 is a crucial transcription factor involved in 
the regulation of cytokine production, including inter-
leukin-8. In this study, we examined the activation of 
STAT3 by BK and SUM in endothelial cells, determin-
ing the protein expression of STAT3 phosphorylated 
at Tyr-705 and total STAT3 protein, with the Western 
blotting technique (Fig. 6A). The pSTAT3/STAT3 ratio 
was calculated after quantification of the corresponding 
bands by densitometric analysis. The values were nor-
malized to the β-actin protein expression and the results 
were presented as a relative ratio in comparison to the 
value for the untreated cells, which was assumed to be 1 
(Fig. 6B). The BK-stimulated cells showed a significant 
increase in STAT3 phosphorylation (by 63%), whilst this 
ratio in the SUM-treated sample was similar to that in 
the untreated cells. Contrarily, the co-stimulation with 
BK and SUM reversed the BK-induced effect, showing 
even a significant decrease in the pSTAT3/STAT3 ratio 
compared to the untreated cells (by 31%).
DISCUSSION
Numerous studies have confirmed that leukocyte ad-
hesion to endothelial cells plays an important role in the 
pathogenesis of a variety of diseases. An imbalance be-
tween the production and degradation of proinflammato-
ry stimuli causes uncontrolled leukocyte adhesion to the 
vascular wall leading to the development of atherosclero-
sis (Langer & Chavakis, 2009). Our current study aimed 
to validate the possible role of the B2R and D2R in the 
regulation of neutrophil adhesion to endothelial cells. 
The analyzed immortalized endothelial cell line isolated 
from the human umbilical vein expresses both receptors 
endogenously, confirming earlier reports of the expres-
sion of these receptors in endothelial cells (Zarei et al., 
2006; Terzuoli et al., 2014). In accordance with previous 
reports (Schuschke et al., 2001; Guevara-Lora et al., 2011), 
the current study indicated that BK increased the PMN 
adhesion to endothelial cells, with a maximal response 
observed after 6 hours of cell incubation (Fig. 1A). 
However, co-stimulation of the cells with SUM and BK 
abolished the BK-induced effect. The absence of SUM 
involvement in cell adhesion and the inversion of the 
BK-induced effect by HOE 140, i.e. a B2R antagonist 
(Fig. 1B and 1C), allow us to suggest that co-activation 
of B2R and D2R modified cell response due to a coop-
Figure 5. IL-8 release by TNF-α-treated endothelial cells after 
stimulation with B2R and D2R agonists. 
Confluent cells were preincubated with 10 ng/ml TNF-α for 24 
hours, followed by the stimulation with 100 nM BK, 100 nM SUM, 
or both agonists for 6 hours (A). Some samples were additionally 
pretreated with 10 μM HOE 140 (B) or 10 μM eticlopride (C) for 30 
minutes before receptor agonist treatment. The production of IL-8 
protein was determined by ELISA and normalized to the amount 
of protein in the samples. The value for the untreated cells is pre-
sented as a dashed line. The bars show the mean values ± S.D. 
from at least three experiments in triplicate. *p<0.05 versus BK-
treated cells, #p<0.05 versus SUM-treated cells, &p<0.05 versus eti-
clopride/SUM-treated cells.
Figure 6. STAT3 activation in endothelial cells treated with B2R 
and D2R agonists. 
After 15min stimulation of confluent cells with 100 nM BK, 100 nM 
SUM, or both agonists simultaneously for 15 minutes, the levels 
of pSTAT3 Tyr-705 and STAT3 protein expression were analyzed 
by Western blotting (A). The pSTAT3/STAT3 ratio (B) was quanti-
fied by densitometric analysis and normalized to the amount 
of β-actin. The bars represent the mean values ± S.D. from three 
independent experiments, which was compared to the value cal-
culated for untreated cells, assumed to have a ratio equal to 1 
(dashed line).*p<0.01 versus BK-treated cells, #p<0.01 versus SUM-
treated cells.
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eration between these receptors. Therefore, here we re-
port for the first time on the protective role of D2R in 
the PMN adhesion to endothelial cells, induced by BK, 
which is in agreement with previous studies demonstrat-
ing anti-inflammatory activity of this receptor (Zhang 
et al., 2015; Konkalmatt et al., 2016). Interestingly, the 
longer incubation produced an opposite effect, i.e. en-
hanced neutrophil adhesion after the co-treatment with 
BK and SUM. This observation may be associated with 
the emergence of other stimuli that can promote pro-
inflammatory response, e.g. overexpression of B1R due 
to prolonged B2R stimulation (Guevara-Lora et al., 2009) 
or activation of signaling pathways promoting chemot-
actic activity (Koyama et al., 2000). Indeed, B1R media-
tion in the interaction between PMN and endothelial 
cells has been reported (Figueroa et al., 2015). The B1R 
agonist, Lys-des-Arg9 bradykinin, induced the expression 
of adhesion molecules in neutrophils and in endothelial 
cells, resulting in enhanced adhesiveness between cells. 
The observations resulting from experiments with the 
B2R antagonist make these assumptions more feasible, 
since the adhesiveness induced by BK is significantly 
decreased only at short incubation times. However, we 
cannot exclude an option that a growing amount of 
B1R molecules can block the interaction between B2R 
and D2R. The dimerization between B2R and B1R has 
been demonstrated (Kang et al., 2004). This assumption 
makes our hypothesis more realistic, because the prein-
cubation of the cells with the B2R and D2R antagonists 
did not reduce adhesion of cells stimulated with both 
agonists (Fig. 1C). Therefore, we summarize that dimin-
ished interactions between PMN and endothelial cells 
can be attributed to the cooperative action of B2R and 
D2R. In our study, we also analyzed the effect of BK 
and SUM on the PMN adhesion to endothelial cells that 
were previously activated with TNF-α, mimicking the 
situation in an inflamed tissue. The TNF-α-preincubated 
cells showed significant changes in PMN adhesion to 
endothelial cells compared to that achieved in cells that 
were not activated with this cytokine, especially after the 
longer incubation with the agonists (Fig. 2). In this case, 
the longer incubation with both agonists, SUM and BK, 
strongly reduced the amount of PMN adhering to the 
endothelial cells, confirming the anti-inflammatory prop-
erties of the D2R agonist. Therefore, D2R activation 
may protect endothelial cells from imbalanced adhesion 
of leukocytes, even during severe inflammation.
Leukocyte adhesion to endothelial cells depends on 
the expression of adhesion molecules in the cell mem-
brane. In this study, we observed that the BK-induced 
effect on PMN-endothelial adhesion was mainly re-
lated to an increase in the expression of E-selectin 
and ICAM-1 protein at the endothelial cell membrane 
(Fig. 3). These results agree with previous studies in-
dicating the role of BK in the regulation of neutrophil 
rolling and sticking to endothelial cells through the in-
duction of E-selectin and ICAM-1 expression (Shige-
matsu et al., 2002). As in the experiments performed on 
PMN-endothelial cell adhesion, SUM did not exert any 
significant effect on the level of adhesion molecule pro-
teins. Nevertheless, a reduced amount of E-selectin and 
ICAM-1 was observed in the BK+SUM-treated cells, 
confirming that the D2R agonist downregulated the BK-
induced effect. The role of D2R in the modulation of 
adhesion proteins has been poorly studied. To date, one 
recent study has shown that D2R silencing in mice after 
intracerebral hemorrhage may induce ICAM-1 expression 
(Zhang et al., 2015). Hence, the present study provides 
new facts on the D2R contribution to the regulation of 
the expression of adhesion proteins in endothelial cells. 
The absence of changes in VCAM-1 expression that 
can be related to lower constitutive expression of this 
protein in endothelial cells, compared to ICAM-1 or E-
selectin, should be noted (Panes et al., 1999). The West-
ern blotting results from samples treated with SUM or 
BK+SUM for 6 hours showed an opposite effect (Fig. 
4). The total protein expression of E-selectin and ICAM-
1 significantly increased, which can be associated with 
enhanced production of proteins due to relocation to the 
cell membrane. Unexpectedly, we observed only a weak 
effect of the receptor agonists on the production of 
ICAM-1 after 24-h incubation. It should be emphasized 
that expression of adhesion proteins is dependent on the 
stimulation time and that the ICAM-1 expression is the 
most sustainable (Scholz et al., 1996; Panes et al., 1999). 
Therefore, we can assume that a balance between de novo 
protein synthesis and ICAM-1 relocation was achieved 
and that, at least after stimulation with BK+SUM, the 
increased amount of this protein may be responsible for 
the increased cell interaction (Fig. 1A).
The endothelial cells did not show any significant pro-
duction of chemokine IL-8 after the stimulation with the 
B2R and D2R agonists (data not shown). However, the 
cell pretreatment with TNF-α facilitated detection of a 
varied influence of the B2R and D2R agonists on IL-8 
release (Fig. 5). These results corroborate our sugges-
tion that the specific D2R agonists can down-regulate 
uncontrolled adhesion of leukocytes to the endothelium 
induced by BK. However, we cannot exclude that in-
creased B1R expression due to cytokine treatment may 
mediate cell adhesion. Of course, we observed that en-
dothelial cells treated with TNF-a showed greater capac-
ity to bind more amounts of neutrophils. Nevertheless, 
HOE 140 abolished the action of BK, which confirmed 
the concerted participation of B2R. Instead, the inhibi-
tion of IL-8 release achieved after the BK+SUM stim-
ulation was not changed by HOE 140, but eticlopride 
reversed this effect, suggesting that the effect can be at-
tributed to direct cooperation between B2R and D2R. 
Therefore, our study provides new information that can 
be helpful for better understanding of the modulation of 
adhesion processes in the vascular wall during inflamma-
tion.
Looking for mechanisms involved in the effects exert-
ed by the co-activation of B2R and D2R on PMN adhe-
sion to endothelial cells, we examined the mediation of 
the transcriptional factor STAT3. This protein modulates 
PMN adhesion to endothelial cells by controlling the 
expression of adhesion molecules (Kim et al., 2017; Wei 
et al., 2018) and interleukin-8 production (Gharavi et al., 
2007). Previous reports have demonstrated an important 
role of BK in the induction of STAT3 phosphorylation 
in endothelial cells. Ju et al. (2000) reported an increased 
pSTAT3 level in bovine aortic endothelial cells 5 minutes 
after B2R activation. Similar results, with a maximal re-
sponse after 15 minutes of BK-induction, were obtained 
in studies performed on a human microvascular endothe-
lial cell line (Guevara-Lora et al., 2014). In this study, we 
demonstrated enhanced STAT3 phosphorylation after 
the 15-min treatment with BK, but it was significant-
ly reduced after the co-stimulation with BK and SUM 
(Fig. 6). These observations correlate with the finding 
discussed above and corroborate the protective role of 
D2R agonists in the inhibition of pro-inflammatory pro-
cesses induced by BK in the vascular system. However, 
additional studies analyzing the B1R involvement should 
be conducted, since this receptor has a great importance 
for leukocyte adhesiveness during chronic inflammation 
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(Figueroa et al., 2015) and is concurrently able to regu-
late STAT3 activation in monocytes (Guevara-Lora et al., 
2014). Although the influence of D2R on the regulation 
of STAT3 phosphorylation has been reported (Kim et 
al., 2010; Qiu et al., 2016), our study showed no signifi-
cant changes in the level of this parameter. However, 
these previous contrary studies were performed in nerv-
ous tissues. Nevertheless, our results provide new facts 
about the mechanism of adhesion modulation by D2R 
and B2R via STAT3 phosphorylation.
In conclusion, the data obtained in this study indicate 
an important role of D2R in the regulation of the ef-
fects exerted by the B2R agonist on the inflammatory re-
sponse of endothelial cells, especially in terms of the reg-
ulation of neutrophil adhesion to endothelial cells. These 
effects seem to be associated with a possible cooperation 
between these receptors, which can be involved in direct 
mutual interactions at the cell membrane, thus modify-
ing their characteristic signaling pathways. The findings 
presented herein enrich the existing knowledge of the 
comprehensive functionality of the endothelium and may 
open up new perspectives in the search for modulators 
of B2 and D2 receptors to develop new drug candidates 
with potential therapeutic activity for treatment of car-
diovascular disorders.
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